
James F. Howard JR, MD, discusses the importance of the expanded label of argenx’s efgartigimod alfa (Vyvgart)

Distinguished Professor of Neurology (Neuromuscular Disorders), Medicine, and Allied Health at the University of North Carolina at Chapel Hill School of Medicine; Chief of the Neuromuscular Disorders Section; Director of the Myasthenia Gravis Clinical Trials and Translational Research Unit